Marc Beer is a known biotech venture capitalist looking for underserved markets in need of solutions. His previous company, Aegerion, where he served as CEO, did that with rare diseases. Now Renovia, Beer’s latest startup, is bringing health options to women all over the world, and the company has $32 million in funding to make it a reality.
From their headquarters in Boston, Renovia is working on diagnostic tools and methods and treatment options for pelvic floor disorders. Such conditions affect roughly 250 million women the world over. The company entered the market for the first time back in April when its flagship product Leva received FDA approval.
Missouri’s Ascension Ventures and Perceptive Advisers in New York helped Beer secure funding from the Longwood Fund. Those tens of millions came from an ideal partner that’s been increasing their investment in the healthcare industry. With that backing from the Longwood Fund, Renovia can go on to complete its next three products and a new version of Leva.
Beer expressed his enthusiasm in a statement that went on to state that the company is now focused on moving forward with developing new healthcare options for hundreds of millions of women. Renovia has its own technologies and digital platforms that aim to inform patients so they have a better understanding of the treatment they’re receiving and the options available to address their pelvic floor disorders.
Beer left his former company Aegerion to form Renovia in 2015.
About Marc Beer:
Marc Beer is a healthcare venture capitalist from the United States. He’s a graduate of Miami University (Ohio) where he sat on the Business Advisory Council. He took to the biotech industry when starting out his career. Abbott Laboratories is where he got his start, working on sales and marketing for pharmaceuticals. Marc cat on the Mass Life Science Board of the Commonwealth and the Bio (Biotechnology Industry Organization) Emerging Technologies Governing Board. When he went to work for Genzyme, working on diagnosing and treating rare diseases, Marc ascended to the role of Vice President. Learn more: https://ideamensch.com/marc-beer/
In 2007, Marc left other companies behind and went on to found his own. ViaCell was a company that dealt in umbilical cord stem cells. It grew to a size of 300 employees and was eventually sold off to competitor PerkinElmer. His executive experience came into play when starting his next venture. With partners Yolanda Lorie and Ramon Iglesias, MD, Marc created Aegerion Pharmaceuticals wher he served as CEO. Operating in 36 countries, this company identified and provided treatment options for rare diseases. After leaving in 2015, Marc founded Renovia, a women’s healthcare company focusing on pelvic floor dysfunction by providing diagnostic information and treatment that gives patients informed options.